President Obama’s year-old, $200 million Precision Medicine initiative (PMI) seems to be doing exactly what was intended, writes Heather Gartman.
Heather Gartman
Advertisement
Heather Gartman is Regional Managing Director (DC), inVentiv Health
Articles by Heather Gartman
Advertisement
Latest Updated Articles
- What “Precision Medicine” Means for Rare Diseases
March 3rd 2016
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial
3
What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely?
4
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
5